Drug intelligence / Profile preview

TopiCanna

Development stage: Unknown
Modality: Small Molecules
Administration: Topical

Overview

TopiCanna is a branded topical cannabis-based product formulated for transdermal or dermal delivery of phytocannabinoids, typically including delta-9-tetrahydrocannabinol (THC) and/or cannabidiol (CBD), for localized relief of pain, inflammation, or other symptoms without producing strong systemic psychoactive effects. By activating cannabinoid receptors (primarily CB1 and CB2) in the skin and underlying tissues, as well as interacting with local inflammatory pathways, TopiCanna is intended to modulate nociception and inflammatory responses at the application site. It is marketed within the medical/recreational cannabis space rather than as a conventional approved pharmaceutical, and detailed composition, potency, and clinical data are not standardized across jurisdictions or producers.

Brand names: TopiCanna

Beyond the preview

Go deeper on TopiCanna.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TopiCanna.

Explore the full profile